Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 2Q

Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 2Q

2Q Revenues: $11.3 billion (+92%)

2Q Earnings: $780.2 million (-51%)

YTD Revenues: $22.8 billion (earnings were $11.3 billion YTD09)

YTD Earnings: $1.1 billion (-64%)

Comments: Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Zetia sales were $564 million (+1%) and Vytorin sales were $490 million (-8%). Isentress sales jumped 55% to $267 million. Cozaar/Hyzaar sales were down 46% to $485 million due to generic competition. Results in the quarter and YTD include $1.7 billion and $4.0 billion, respectively, of merger-related expenses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters